SYN logo

Synthetic Biologics (SYN) Cash And Cash Equivalents

Annual Cash & Cash Equivalents

$67.33 M
+$61.10 M+981.18%

December 31, 2021

Summary

Performance

1-Year Change

+981.18%

3-Year Change

+132.81%

5-Year Change

+293.35%

15-Year Change

+293.35%

SYN Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$67.33 M
SYN annual cash & cash equivalents is currently at an all-time high

3-Year Low

$67.33 M
SYN annual cash & cash equivalents is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2021
SYN previous annual earnings announcement was published on Dec 31, 2021

Next Annual Earnings Report Date

N/A
SYN next annual earnings announcement has not yet been scheduled

OtherSYNbalance sheetmetrics:

Quarterly Total Assets

$82.33 M
SYN quarterly total assets is $82.33 million

Quarterly Current Assets

$54.89 M
SYN quarterly total current assets is $54.89 million

Quarterly Total Liabilities

$20.66 M
SYN quarterly total liabilities is $20.66 million

Quarterly Current Liabilities

$13.26 M
SYN quarterly total current liabilities is $13.26 million

Quarterly Cash And Cash Equivalents

$52.27 M
-$4.43 M-7.81%

June 30, 2022

Summary

Performance

3-Month Change

-7.81%

1-Year Change

-29.65%

3-Year Change

+140.72%

5-Year Change

+290.74%

SYN Quarterly Cash And Cash Equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$76.89 M
SYN quarterly cash and cash equivalents is currently -32.02% below its historical high of $76.89 million

3-Year Low

$52.27 M
SYN quarterly cash and cash equivalents is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2022
SYN previous earnings announcement was published on Jun 30, 2022

Next Quarterly Earnings Report Date

N/A
SYN next earnings announcement has not yet been scheduled

OtherSYNbalance sheetmetrics:

Quarterly Total Assets

$82.33 M
SYN quarterly total assets is $82.33 million

Quarterly Current Assets

$54.89 M
SYN quarterly total current assets is $54.89 million

Quarterly Total Liabilities

$20.66 M
SYN quarterly total liabilities is $20.66 million

Quarterly Current Liabilities

$13.26 M
SYN quarterly total current liabilities is $13.26 million

Cash And Cash Equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

SYN Cash And Cash Equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+981.2%-29.6%
3 y3 years+132.8%+140.7%
5 y5 years+293.4%+290.7%

SYN Cash And Cash Equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat highat low-22.4%at low
5 y5-yearat high-90.8%-32.0%-88.5%
alltimeall timeat high-99.9%-32.0%-99.8%

Synthetic Biologics Cash And Cash Equivalents History

DateAnnualQuarterly
Jun 2022
-
$52.27 M(-7.8%)
Mar 2022
-
$56.69 M(-15.8%)
Dec 2021
$67.33 M(+981.2%)
$67.33 M(-6.7%)
Sep 2021
-
$72.14 M(-2.9%)
Jun 2021
-
$74.29 M(-3.4%)
Mar 2021
-
$76.89 M(+1134.7%)
Dec 2020
$6.23 M(-58.6%)
$6.23 M(+3.7%)
Sep 2020
-
$6.00 M(-25.5%)
Jun 2020
-
$8.06 M(-20.1%)
Mar 2020
-
$10.09 M(-33.0%)
Dec 2019
$15.04 M(-48.0%)
$15.04 M(-19.3%)
Sep 2019
-
$18.65 M(-14.1%)
Jun 2019
-
$21.71 M(-12.1%)
Mar 2019
-
$24.69 M(-14.6%)
Dec 2018
$28.92 M(+69.0%)
$28.92 M(+202.8%)
Sep 2018
-
$9.55 M(+33.9%)
Jun 2018
-
$7.13 M(-35.4%)
Mar 2018
-
$11.04 M(-35.5%)
Dec 2017
$17.12 M(-10.2%)
$17.12 M(-18.7%)
Sep 2017
-
$21.05 M(+57.4%)
Jun 2017
-
$13.38 M(-0.7%)
Mar 2017
-
$13.47 M(-29.3%)
Dec 2016
$19.05 M(-8.5%)
$19.05 M(+318.9%)
Sep 2016
-
$4.55 M(-54.7%)
Jun 2016
-
$10.05 M(-33.5%)
Mar 2016
-
$15.10 M(-27.5%)
Dec 2015
$20.82 M(+18.8%)
$20.82 M(-34.5%)
Sep 2015
-
$31.81 M(+568.6%)
Jun 2015
-
$4.76 M(-60.5%)
Mar 2015
-
$12.05 M(-31.2%)
Dec 2014
$17.52 M(+19.8%)
$17.52 M(+433.3%)
Sep 2014
-
$3.29 M(-58.1%)
Jun 2014
-
$7.84 M(-29.7%)
Mar 2014
-
$11.15 M(-23.7%)
Dec 2013
$14.63 M(+46.9%)
$14.63 M(+184.3%)
Sep 2013
-
$5.14 M(-25.2%)
Jun 2013
-
$6.88 M(-19.3%)
Mar 2013
-
$8.52 M(-14.4%)
Dec 2012
$9.95 M(+49.1%)
$9.95 M(+117.5%)
Sep 2012
-
$4.58 M(-22.8%)
Jun 2012
-
$5.93 M(-12.8%)
Mar 2012
-
$6.80 M(+1.9%)
Dec 2011
$6.68 M(+152.1%)
$6.68 M(+44.9%)
Sep 2011
-
$4.61 M(-45.0%)
Jun 2011
-
$8.39 M(+37.9%)
Mar 2011
-
$6.08 M(+129.5%)
Dec 2010
$2.65 M(-2.4%)
$2.65 M(-19.9%)
Sep 2010
-
$3.31 M(+1.1%)
Jun 2010
-
$3.27 M(+65.3%)
Mar 2010
-
$1.98 M(-27.1%)
DateAnnualQuarterly
Dec 2009
$2.71 M(-53.6%)
$2.71 M(-23.1%)
Sep 2009
-
$3.53 M(-20.1%)
Jun 2009
-
$4.42 M(-16.4%)
Mar 2009
-
$5.29 M(-9.7%)
Dec 2008
$5.86 M(-49.0%)
$5.86 M(-9.0%)
Sep 2008
-
$6.44 M(-13.7%)
Jun 2008
-
$7.45 M(-14.9%)
Mar 2008
-
$8.76 M(-23.8%)
Dec 2007
$11.49 M(-5.7%)
$11.49 M(+56.3%)
Sep 2007
-
$7.35 M(-19.3%)
Jun 2007
-
$9.11 M(-16.7%)
Mar 2007
-
$10.94 M(-10.3%)
Dec 2006
$12.19 M(+953.1%)
$12.19 M(+7389.2%)
Dec 2005
$1.16 M(+253.9%)
-
Mar 2003
-
$162.80 K(-50.2%)
Dec 2002
$327.20 K(-61.9%)
$327.20 K(-6.0%)
Sep 2002
-
$348.10 K(-59.3%)
Jun 2002
-
$855.90 K(-19.0%)
Mar 2002
-
$1.06 M(+23.0%)
Dec 2001
$859.30 K(-71.8%)
$859.30 K(-59.4%)
Sep 2001
-
$2.12 M(+44.7%)
Jun 2001
-
$1.46 M(-38.5%)
Mar 2001
-
$2.38 M(-21.7%)
Dec 2000
$3.04 M(-21.5%)
$3.04 M(+85.0%)
Sep 2000
-
$1.64 M(-10.9%)
Jun 2000
-
$1.85 M(-47.1%)
Mar 2000
-
$3.49 M(-10.0%)
Dec 1999
$3.87 M(+55.0%)
$3.87 M(+384.3%)
Sep 1999
-
$800.00 K(-38.5%)
Jun 1999
-
$1.30 M(-31.6%)
Mar 1999
-
$1.90 M(-24.0%)
Dec 1998
$2.50 M(+525.0%)
$2.50 M(-3.8%)
Sep 1998
-
$2.60 M(-51.9%)
Jun 1998
-
$5.40 M(+1250.0%)
Dec 1997
$400.00 K(-80.0%)
$400.00 K(-60.0%)
Sep 1997
-
$1.00 M(+100.0%)
Jun 1997
-
$500.00 K(-83.3%)
Mar 1997
-
$3.00 M(+50.0%)
Dec 1996
$2.00 M(+5.3%)
$2.00 M(-42.9%)
Sep 1996
-
$3.50 M(-32.7%)
Jun 1996
-
$5.20 M(+160.0%)
Mar 1996
-
$2.00 M(+5.3%)
Dec 1995
$1.90 M(+1800.0%)
$1.90 M(-36.7%)
Sep 1995
-
$3.00 M(+2900.0%)
Dec 1994
$100.00 K(-94.1%)
$100.00 K(-97.7%)
Mar 1994
-
$4.40 M(+158.8%)
Dec 1993
$1.70 M
$1.70 M(-39.3%)
Sep 1993
-
$2.80 M(-33.3%)
Jun 1993
-
$4.20 M(-8.7%)
Mar 1993
-
$4.60 M

FAQ

  • What is Synthetic Biologics annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Synthetic Biologics?
  • What is Synthetic Biologics annual cash & cash equivalents year-on-year change?
  • What is Synthetic Biologics quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Synthetic Biologics?
  • What is Synthetic Biologics quarterly cash and cash equivalents year-on-year change?

What is Synthetic Biologics annual cash & cash equivalents?

The current annual cash & cash equivalents of SYN is $67.33 M

What is the all time high annual cash & cash equivalents for Synthetic Biologics?

Synthetic Biologics all-time high annual cash & cash equivalents is $67.33 M

What is Synthetic Biologics annual cash & cash equivalents year-on-year change?

Over the past year, SYN annual cash & cash equivalents has changed by +$61.10 M (+981.18%)

What is Synthetic Biologics quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of SYN is $52.27 M

What is the all time high quarterly cash and cash equivalents for Synthetic Biologics?

Synthetic Biologics all-time high quarterly cash and cash equivalents is $76.89 M

What is Synthetic Biologics quarterly cash and cash equivalents year-on-year change?

Over the past year, SYN quarterly cash and cash equivalents has changed by -$22.02 M (-29.65%)